Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | COMT | P21964 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940495 | 1.00 | FTO (0.73) | FTOMEN1KMT2AMAPTKDM4E | |
| SCHEMBL16680886 | 1.00 | FTO (0.73) | FTOMEN1KMT2AMAPTKDM4E | |
| SCHEMBL20100865 | 0.88 | FTO (0.74) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8848272 | 0.88 | FTO (0.74) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8848276 | 0.88 | FTO (0.74) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8848281 | 0.88 | FTO (0.74) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL15920344 | 0.86 | FTO (0.73) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL20100868 | 0.86 | FTO (0.73) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28720710 | 0.86 | FTO (0.73) | FTOMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29043423 | 0.83 | FTO (0.72) | FTOMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266823-B2 | Compositions and methods for the treatment of parkinson's disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-02-23 | — | — | US | claimed |
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | claimed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | claimed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | claimed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | claimed |
| US-20080004343-A1 | Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide | WOCKHARDT LIMITED | 2008-01-03 | — | — | US | disclosed |
| WO-2007113845-A1 | A PROCESS FOR THE PREPARATION OF (E)-2-CYANO-3-(3, 4-DIHYDROXY-5-NITROPHENYL)-N, N-DIETHYL-2-PROPENAMIDE (ENTACAPONE) | ALEMBIC LIMITED (IN) | 2007-10-11 | — | — | WO | disclosed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | disclosed |
| US-5489614-A | MEDICINAL ANTIOXIDANTS USED IN PREVENTION AND TREATMENT OF TISSUE DAMAGE INDUCED BY LIPID PEROXIDATION | ORION-YHTYMA OY (FI) | 1996-02-06 | — | — | US | disclosed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | disclosed |
| US-5283352-A | Transferase inhibitor | ORION-YHTYMA OY (FI) | 1994-02-01 | — | — | US | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | disclosed |
| EP-0426468-A2 | Stabile polymorphic form of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide and the process for its preparation | ORION-YHTYMÄ OY (FI) | 1991-05-08 | — | — | EP | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004343-A1 | Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide | GNE, HTR3E, HLA-C | FTO 1988/4885MEN1 4125/4885KMT2A 4773/4885 |
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | PARK7, HTT, SNCA | FTO 3419/4885MEN1 1288/4885KMT2A 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.